Related Experiment Videos
[The triple test scenario for Styria. With data of the Styria Abnormalities Register]
M C Häusler1, A Berghold, H Zierler
1Geburtshilflich-Gynäkologische Universitätsklinik, Karl-Franzens-Universität, Graz, Osterreich.
Gynakologisch-Geburtshilfliche Rundschau
|January 1, 1996
Summary
The triple-marker screening for trisomy 21 (triple test) in Austria is cost-effective, especially for women 35 and older, or all pregnant women if maximizing detection rates is prioritized. This suggests replacing current maternal age screening policies.
Area of Science:
- Medical Screening
- Prenatal Diagnostics
- Health Economics
Context:
- Trisomy 21 (Down syndrome) screening is crucial for prenatal care.
- Austria currently relies on maternal age screening.
- Cost-effectiveness of screening methods requires evaluation.
Purpose:
- To conduct a cost-effectiveness analysis of the triple-marker screening for trisomy 21 in Austria.
- To determine optimal implementation strategies for the triple test.
- To compare maternal serum screening with existing policies.
Summary:
- A cost-effectiveness analysis combined published triple-test data with the Styrian Malformation Register (1985-1992).
- Analysis considered total prenatal diagnosis costs, cost per affected fetus, detection rates, and procedure-related losses.
- Results indicate offering the triple test to women aged 35+ prioritizes low costs, while offering it to all pregnant women prioritizes high detection rates.
Impact:
- The study suggests replacing Austria's current maternal age screening policy with maternal serum screening.
- Implementation of the triple test can improve prenatal diagnosis efficiency.
- Optimized screening strategies can enhance detection of trisomy 21, informing public health decisions.